Meeting
2024 ASCO Genitourinary Cancers Symposium
CaboLu: A phase 1b study of cabozantinib (cabo) in combination with lutetium (Lu 177) vipivotide tetraxetan (LVT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Gliceida Galarza Fortuna
Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
Gliceida Galarza Fortuna , Colin Moynier , Kenneth M. Boucher , Blake Nordblad , Matthew Covington , Gabriel Fine , Susan Clement , Michelle Esplin , Manish Kohli , Sumati Gupta , Benjamin L. Maughan , Neeraj Agarwal , Umang Swami
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05613894
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr TPS251)
DOI
10.1200/JCO.2024.42.4_suppl.TPS251
Abstract #
TPS251
Poster Bd #
Q12
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer.
First Author: A. Oliver Sartor
Poster
2020 Genitourinary Cancers Symposium
VISION: An international, prospective, open-label, multicenter, randomized phase III study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
First Author: A. Oliver Sartor
Poster
2015 Genitourinary Cancers Symposium
Association of changes in biomarkers with treatment with cabozantinib (Cabo) in metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the 100mg nonrandomized expansion cohort of a randomized discontinuation trial.
First Author: Melania Pintilie
Poster
2024 ASCO Genitourinary Cancers Symposium
Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT).
First Author: Colin P Bergstrom